Symbols

How did NEO's revenue and expenses trend in Q4 2024?

5/8/2025 05:25am

Aime

Neogenomics (NEO) reported a net loss of $15.32 million in Q4 2024, with operating expenses amounting to $7.97 million and research and development (R&D) expenses at $6.81 million¹. The company's revenue by business is not available, but the negative net income indicates a challenging financial period.

1/2

NEO Revenue By Business

Source:

1. NEO Revenue by Business, Net Income, Operating Expenses, Research and Development Expenses, Sales and Marketing Expenses in Q4 2024